This model showed that Sox2 was complementary to hormone receptors ER and AR in predicting cancer progression, and also showed that ER and AR exerted opposite prognostic effects in FMCs, as increased ER expression was associated with cancer aggressiveness (recurrence, metastasis). Here, SOX2 is linked to cancer.